Sanofi: Dupixent® (dupilumab) approved by FDA as 1rst and only treatment indicated for prurigo nodularis

 

• Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
• About 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options
• Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S.

https://www.globenewswire.com/news-release/2022/09/28/2524764/0/en/Press-Release-Dupixent-dupilumab-approved-by-FDA-as-the-first-and-only-treatment-indicated-for-prurigo-nodulari